Advertisement

Topics

EMERGENT TECHNOLOGIES, INC Company Profile

12:32 EST 20th November 2017 | BioPortfolio

Our unique process matches breakthrough technology developed at Universities or Research Institutions with commercialization partners who validate the technology and the market potential, thus reducing risk and accelerating the technology to market. We establish and manage companies that hold exclusive licenses and rights to technology that has had significant research funding and that is ready to be commercialized. Our value add is to form partnerships with large international companies pursuing major markets and managing the development process to bring the technology, products and services to market in a timely manner

Location

2508 Ashley Worth Blvd.Suite 200

Austin
Texas
78738
United States of America

Contact

Phone: 512) 263-3232
Fax: 512) 263-3236
Email: info@emergenttechnologies.com


News Articles [271 Associated News Articles listed on BioPortfolio]

Emergent BioSolutions embarks on another spending spree

Shares of US biotech firm Emergent BioSolutions closed up 3.3% at $36.04 yesterday, after it announced…

Emergent BioSolutions to acquire anthrax treatment, move manufacturing to Baltimore

Emergent BioSolutions, a Gaithersburg-based drug maker with facilities in Baltimore, has acquired a drug used to treat anthrax from GlaxoSmithKline in a deal worth up to $96 million. Under the deal an...

GSK's raxibacumab acquired by Emergent for $76M upfront

GlaxoSmithKline granted Emergent BioSolutions rights to regulatory approvals and intellectual property rights for its FDA-app -More- 

Emergent files paperwork for new immuno-oncology spin-off

Emergent BioSolutions announced April 15 that it has begun the formal process of separating some of its assets to form a separate entity, which will be known as Aptevo Therapeutics Inc. Read more..

$175.41 Million in Sales Expected for Emergent Biosolutions, Inc. (EBS) This Quarter

Equities analysts predict that Emergent Biosolutions, Inc. will announce sales of $175.41 million for the current quarter, Zacks reports. Two analysts have provided estimates for Emergent Biosolutions...

Emergent buys anthrax mAb raxibacumab from GSK, takes on BARDA deal

Emergent BioSolutions Inc. says transferring production of the anthrax countermeasure raxibacumab from GSK will be completed in 2020.

Emergent buys Abec bioreactor for BioThrax facility

Bioterrorism countermeasure manufacturer Emergent Biosciences has bought a 4,000L bioreactor developed by Abec.

Emergent buys Abec bioreactor to transfer raxibacumab to Baltimore facility

Bioterrorism countermeasure manufacturer Emergent Biosciences has bought a 4,000L bioreactor developed by Abec.

PubMed Articles [457 Associated PubMed Articles listed on BioPortfolio]

Mortality Following Emergent Trauma Laparotomy: a Multicenter, Retrospective Study: Mortality after Emergent Trauma Laparotomy.

Two decades ago, hypotensive trauma patients requiring emergent laparotomy had a 40% mortality. In the interim, multiple interventions to decrease hemorrhage-related mortality have been implemented bu...

Emergent cholecystectomy is superior to percutaneous cholecystostomy tube placement in critically ill patients with emergent calculous cholecystitis.

The role of percutaneous cholecystostomy (PC) is undefined in patients with multiple comorbidities presenting with emergent calculous cholecystitis (CC). This study compared outcomes between PC, lapar...

Telehealth and eHealth interventions for posttraumatic stress disorder.

This paper presents existing research describing how telehealth and eHealth technologies can be used to improve mental health services for trauma survivors, either by enhancing existing treatment appr...

What can Parents' Self-report of Reading Difficulties Tell Us about Their Children's Emergent Literacy at School Entry?

Research has linked family risk (FR) of reading difficulties (RD) with children's difficulties in emergent literacy development. This study is the first to apply parents' self-report of RD as a proxy ...

Delta neutrophil index as a promising prognostic marker of emergent surgical intervention for acute diverticulitis in the emergency department.

Early identification of patients with acute diverticulitis who require emergent surgical intervention in the emergency department (ED) is important to the physician. Although computed tomography (CT) ...

Clinical Trials [446 Associated Clinical Trials listed on BioPortfolio]

Multifactorial Approach to Emergent Cerclage

Though cervical insufficiency is a common cause of second trimester pregnancy loss, the placement of an emergent cerclage in these patients is thought to improve perinatal outcomes. It is ...

Pre-hospital and Intra-hospital Temporal Delays in Patients Requiring Emergent Trauma Craniotomy

The investigators aim to retrospectively map the delays in the acute care of traumatic brain injury patients necessitating emergent craniotomies.

Assessing Treatment Emergent Suicidal Ideation in Patients With Major Depression

This study will develop a new methodology to evaluate any treatment-emergent suicidal ideation that might occur when an antidepressant treatment has been started and/or during times when d...

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

The goal of this study is to determine if a fixed dose of 4-factor prothrombin complex concentrate (4FPCC) is as effective as the current standard of care. 4FPCC is used to reverse the eff...

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

This is a randomized, active comparator-controlled, parallel-group, multi-site, double-blind safety trial of sugammadex (MK-8616) for the reversal of neuromuscular blockade (NMB) induced b...

Companies [1249 Associated Companies listed on BioPortfolio]

Emergent Health Corp.

Emergent Health Corp., a diversified biotechnology firm, is focused on the health and wellness industry. Using patented and patent pending nutritionally designed products, E...

Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the bodyâ€...

Emergent Financial Group, Inc.

Emergent Financial Group provides investment banking services for early stage growth companies in healthcare. By specializing on innovative healthcare companies, Emergent has deve...

Emergent Technologies, Inc.

Headquartered in Austin, Texas, Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company that identifies, manages, develops and partners to turn game-chang...

Virtual Radiologic Corp.

Virtual Radiologic Corporation (vRad) is a national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in pa...

More Information about "EMERGENT TECHNOLOGIES, INC" on BioPortfolio

We have published hundreds of EMERGENT TECHNOLOGIES, INC news stories on BioPortfolio along with dozens of EMERGENT TECHNOLOGIES, INC Clinical Trials and PubMed Articles about EMERGENT TECHNOLOGIES, INC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EMERGENT TECHNOLOGIES, INC Companies in our database. You can also find out about relevant EMERGENT TECHNOLOGIES, INC Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record